Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DM...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2018
|
| Acceso en línea: | http://eprints.uanl.mx/29854/7/29854.pdf |
| _version_ | 1838551024172793856 |
|---|---|
| author | Cuervo Lozano, Edgar González Cortés, Jesús Hernán Olvera Barrios, Abraham Treviño Cavazos, Ezequiel Rodríguez Pedraza, Josué Mohamed Noriega, Karim Mohamed Hamsho, Jesús |
| author_facet | Cuervo Lozano, Edgar González Cortés, Jesús Hernán Olvera Barrios, Abraham Treviño Cavazos, Ezequiel Rodríguez Pedraza, Josué Mohamed Noriega, Karim Mohamed Hamsho, Jesús |
| author_sort | Cuervo Lozano, Edgar |
| collection | Repositorio Institucional |
| description | AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME).
METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo.
RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3 ; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 μm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn’t show significant improvement of any variable.
CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME. |
| format | Article |
| id | eprints-29854 |
| institution | UANL |
| language | English |
| publishDate | 2018 |
| record_format | eprints |
| spelling | eprints-298542025-07-08T16:23:09Z http://eprints.uanl.mx/29854/ Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema Cuervo Lozano, Edgar González Cortés, Jesús Hernán Olvera Barrios, Abraham Treviño Cavazos, Ezequiel Rodríguez Pedraza, Josué Mohamed Noriega, Karim Mohamed Hamsho, Jesús AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3 ; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 μm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn’t show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME. 2018 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/29854/7/29854.pdf http://eprints.uanl.mx/29854/7.haspreviewThumbnailVersion/29854.pdf Cuervo Lozano, Edgar y González Cortés, Jesús Hernán y Olvera Barrios, Abraham y Treviño Cavazos, Ezequiel y Rodríguez Pedraza, Josué y Mohamed Noriega, Karim y Mohamed Hamsho, Jesús (2018) Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. International Journal of Ophthalmology, 11 (6). pp. 981-985. ISSN 2222-3959 doi:10.18240/ijo.2018.06.14 |
| spellingShingle | Cuervo Lozano, Edgar González Cortés, Jesús Hernán Olvera Barrios, Abraham Treviño Cavazos, Ezequiel Rodríguez Pedraza, Josué Mohamed Noriega, Karim Mohamed Hamsho, Jesús Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| title_full | Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| title_fullStr | Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| title_full_unstemmed | Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| title_short | Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema |
| title_sort | short term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non center involved diabetic macular edema |
| url | http://eprints.uanl.mx/29854/7/29854.pdf |
| work_keys_str_mv | AT cuervolozanoedgar shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT gonzalezcortesjesushernan shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT olverabarriosabraham shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT trevinocavazosezequiel shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT rodriguezpedrazajosue shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT mohamednoriegakarim shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema AT mohamedhamshojesus shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema |